(Reuters) – BioAge Labs said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly’s tirzepatide for the treatment of obesity.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas)
Comments